Article and Video CATEGORIES
GRACE faculty joined live and online participants on April 6, 2019, in Philadelphia, PA to discuss the newest breakthroughs in Targeted Therapies for Lung Cancer
We are working to edit the videos and post them on our site but meanwhile -- please feel free to view the unedited versions now in YouTube (to view the full playlist, click the three lines in the upper left corner. )
To move to the next video in the playlist click SHIFT-N):
Discussions from the patient forum included:
NGS: Current Status, Barriers and Emerging Targets
Joshua Bauml, MD
- Liquid Biopsies as a New Option: How Does it Fit In?
Charu Aggarwal, MD
- What is the Role for Rebiopsy Today?
Hossein Borghaei, DO, MS
- EGFR: initial treatment, acquired resistance, Q&A
Helena Yu, MD
H. Jack West, MD
- ALK/ROS1: initial treatment, acquired resistance, Q&A
Charu Aggarwal, MD
Melina Marmarelis, MD
- RET/MET/BRAF: initial treatment, acquired resistance, Q&A
Joshua Sabari, MD
Joshua Bauml, MD
- Challenges and Opportunities in Clinical Research with Narrow Populations
Joshua Sabari, MD
- Immunotherapy for Targeted Therapies -- What Do We Know?
Helena Yu, MD
- Controlling the Brain as a Separate Compartment
H. Jack West, MD
- Paying for Oral Targeted Therapies - Challenges and Pathways to Coverage
Christine Cambareri, PharmD, BCPS, BCOP
- Online Communities - Support, Education & Partnership on Research
Jill Feldman, Patient Advocate
- Online Communities - Facilitating and Partnership in Research
Ivy Elkins, Patient Advocate
View faculty bios here
For questions and comments, please join the conversation in our community forums!
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…